formulary management

ICER-VA alliance for formulary management sparks debateThe National Pharmaceutical Council takes issue with ICER’s collaboration with the VA’s PBM. Find out what both camps are saying.
Potential CVS-Aetna merger: Top 6 industry implicationsHealthcare executives identify how the industry could be affected if the Aetna-CVS merger goes through.
Payers can predict budget implications of high-cost drugs in the pipelineA University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.
Survey: How payers use nonpayer generated data to make formulary decisionsExternal, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Top considerations when determining whether to approve expensive drugsWeighing the ethics of approving expensive cancer drugs for patients facing terminal disease is a multifaceted endeavor. Here are some recommendations.
Expedited FDA approval plays dominant role in drug approvalsLast year was a banner year for generic drug approvals by the FDA. Find out what’s in store for 2017.
Are payers optimistic about biosimilars’ savings?As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.
Four things executives need to know to combat rising drug spendExecutives need to ask themselves four key questions to mitigate the negative impact of rising drug costs.
Best candidates for PCSK9 inhibitors
Best candidates for PCSK9 inhibitorsPBMs, insurers use cautious approach when managing these cholesterol-lowering drugs.
Specialty pharmacies: The payer’s dilemma
Specialty pharmacies: The payer’s dilemmaPayers weigh the benefits of using their own resources to develop a specialty pharmacy or contracting outside for services.